Dr. Reddy's Laboratories Limited Revenue 2011-2026 | RDY

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Dr. Reddy's Laboratories Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
190 B	175 B	2.22 B	2.18 B	2.17 B	2.34 B	2.38 B	2.2 B	-	-	1.68 B

All numbers in INR currency

Indicator range from annual reports

Maximum	Minimum	Average
190 B	1.68 B	42.2 B

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
Aurinia Pharmaceuticals AUPH	77.1 M	$ 14.01	-3.78 %	$ 1.88 B	Canada
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	720 M	$ 217.88	-0.08 %	$ 5 B	Danmark
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 19.32	0.47 %	$ 903 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 8.27	-1.9 %	$ 110 M	USA
CytomX Therapeutics CTMX	76.2 M	$ 4.22	-5.27 %	$ 582 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
CollPlant Biotechnologies Ltd. CLGN	15.6 M	$ 0.68	12.29 %	$ 7.79 M	Israel
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	242 K	$ 1.39	-0.73 %	$ 355 M	Britain
Exelixis EXEL	2.32 B	$ 41.57	0.39 %	$ 11.3 B	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
ChemoCentryx CCXI	32.2 M	-	-	$ 3.74 B	USA
Aytu BioScience AYTU	66.4 M	$ 2.61	-0.76 %	$ 16.4 M	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Genmab A/S GMAB	10.1 B	$ 25.69	0.04 %	$ 16.5 B	Danmark
Grifols, S.A. GRFS	7.21 B	$ 7.65	-0.59 %	$ 6.83 B	Spain
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Halozyme Therapeutics HALO	1.4 B	$ 62.11	-1.19 %	$ 7.44 B	USA
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.32	-2.38 %	$ 828 M	Canada
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
Keros Therapeutics KROS	244 M	$ 11.12	-1.07 %	$ 414 M	USA
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA